EGFR and colorectal carcinoma: ,4 As with HCC, the prognosis of CRC is not satisfying, especially for patients with metastasis, although there have been advances in treatment options, including the anti-epidermal growth factor receptor (EGFR) antibody cetuximab and the anti-angiogenesis antibody bevacizumab.4